
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
American Medical Systems Holdings Inc. and Laserscope, two companies with a significant presence in the urology market, have entered into a definitive merger agreement providing for the acquisition of Laserscope by AMS.
American Medical Systems Holdings Inc. and Laserscope, two companies with a significant presence in the urology market, have entered into a definitive merger agreement providing for the acquisition of Laserscope by AMS. The total acquisition price for Laserscope’s shares and options is approximately $715 million.
The acquisition will add a variety of BPH therapy solutions to AMS’s line of modalities and products for the treatment of pelvic disorders in men and women, according to a statement from the companies.





